Biocon Limited — Q3 FY24
Biocon's Q3 FY24 consolidated revenue from operations grew 34% YoY to INR 3,954 crore, driven by a 65% surge in biosimilars revenue, partially offset by a 7% decline in generics.
neutral
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
54%Questions answered3Evaded / deflected12Questions audited
Evasive
High priority
Next steps for Aflibercept and first-to-file opportunity
Asked by Neha Manpuria, Bank of America
Management acknowledged the question but gave no concrete next steps or timeline, only that they are evaluating options.
no specific timelineno commitment to appealvague 'evaluating options'
Read the exchange
Question
If you could just tell us the next steps that Biocon is looking at in terms of Aflibercept, and could this still be an opportunity for us, given our first-to-filing status in the product?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics
As you know, at this point, we are evaluating all the options available to us, and certainly, appeal is one of the options that we are looking at. We are confident about the position that we've got, and as we progress this, we will update you on the next steps.
Partial answer
High priority
Traction of biosimilar revenue and margin improvement timeline
Asked by Neha Manpuria, Bank of America
Addressed revenue growth via market share but did not give a timeline for margin improvement or quantify when one-offs would end.
no specific margin timelinedeferred to new product approvals
Read the exchange
Question
So is it fair to assume, even though there is still uncertainty on the approval timeline for Aspart and Beva, what should be the traction of the biosimilar revenue? That's number one. And second, when will that start reflecting in terms of margins?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics
I think the new products are awaiting inspection at site. There's been good progress on that. But until then, certainly, we are going to look at growing the business through existing products, and that will come from increased market share.
Evasive
High priority
Timeline for new FDA approvals (Aspart, Beva)
Asked by Neha Manpuria, Bank of America
Management provided no specific timeline, only that they await FDA inspection, which is outside their control.
no timeline givendeferred to FDA inspection scheduling
Read the exchange
Question
And when do we expect these new approvals, Shreehas? Would it be this second half of FY 2025, 2026? I mean, what's your sense on when do we eventually see this approval, given the long wait already?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics
I wish I had a more firmer answer for this. ... we are at a point where we are awaiting the FDA to come on site and inspect us, and we should be able to move this forward. There is no outstanding question on the science.
Partial answer
High priority
Net debt reduction path for BBL and comfort level
Asked by Neha Manpuria, Bank of America
Acknowledged priority and gave a past reduction figure but did not provide a specific target or timeline for the next 12 months.
no specific target or timeline for 12 months
Read the exchange
Question
If I look at the BBL net debt to EBITDA, we are tracking over four times net debt to EBITDA. What's the sense of the net debt reduction path that we have for BBL, and what's our comfort level, let's say, 12 months from now?
Peter Bains, Group CEO, Biocon
Clearly, we've identified strengthening the balance sheet and debt reduction as a priority. As I said earlier, we've reduced that by $200 million in the quarter. It will remain a focus. ... we'll be working our way to reduce that over the coming quarters.
Answered
High priority
Pricing pressure in biosimilar contracts and Adalimumab discussions
Asked by Damayanti Kerai, HSBC
Provided specific market share data and acknowledged pricing pressures, directly addressing the question.
Read the exchange
Question
I just want to understand the pricing part of these contracts also, whether we are gaining volume, but how is the scenario on the pricing part? ... what kind of discussions you are undergoing currently for Adalimumab?
Matthew Erick, CCO of Advanced Markets, Biocon Biologics Limited
This business continues to have pricing pressures, which we're seeing uptake in addition to volume in which we're winning in our Fulphila and our Ogivri. ... On Adalimumab, we are seeing wins. We're seeing them steadily progress. It's about 10% of the total U.S. lives.
Evasive
Medium priority
Update on Malaysia plant and Bevacizumab opportunity
Asked by Damayanti Kerai, HSBC
No timeline given for Malaysia plant resolution; for Bevacizumab, management affirmed opportunity but gave no specifics on timing.
no timeline for resolutiondeferred to FDA scheduling
Read the exchange
Question
My second question is on an update on the Malaysia plant. So what are your expectations, and what kind of timeline should we be looking for resolution of issues there? And just another question on bevacizumab. So do you think it's still a meaningful opportunity for you to pursue?
Rhonda Duffy, COO, Biocon Biologics Limited
The Malaysia facility is now awaiting reinspection from the FDA. We have been actively engaged with the FDA and discussing with the agency on a number of occasions. We are patiently waiting for them to arrive for the inspection. We're ready.
Partial answer
High priority
BBL revenue decline and near-term performance concerns
Asked by Surya Patra, PhillipCapital
Management did not directly address the concern about near-term performance but instead explained adjustments to margins.
no direct answer on whether to worryreframed to margin adjustments
Read the exchange
Question
So my question is that, so till the time that we are not seeing incremental revenue from the newer pipeline, so should we be worried about the performance of the BBL in the near-term?
Kedar Upadhye, CFO, Biocon Biologics Limited
See, there are two, three adjustments you need to make before you compute steady-state PBT margins. ... if you make these adjustments, you will get to something which is more steady-state, and that will give you an appropriate idea as to the margin profile.
Answered
High priority
Adalimumab opportunity timing and ramp-up expectations
Asked by Surya Patra, PhillipCapital
Management clearly confirmed the delay to CY 2025 and explained the market dynamics.
Read the exchange
Question
So is it fair to believe that this opportunity is getting extended or delayed to CY 2025, even for us?
Kedar Upadhye, CFO, Biocon Biologics Limited
I think the broad answer to your question is yes. I mean, it's very clear that the market for Adalimumab is not going to open up in a big way in calendar 2024, and the expectation is that that will happen in a more structured fashion in calendar 2025.
Answered
High priority
Competitive dynamics for Semglee and market share upside
Asked by Shyam Srinivasan, Goldman Sachs
Provided specific market share numbers and discussed competitive positioning and payer wins.
Read the exchange
Question
Just want to understand, when we look at the pipeline for 2024 calendar year, I think two Chinese insulin guys are likely to be in the market. ... what do you think about the competitive landscape for Semglee? Is there still upside?
Matthew Erick, CCO of Advanced Markets, Biocon Biologics Limited
We continue to see progress, nice progress, with our market access with insulin Glargine. ... we have one and secured two large payers that started 1/1/2024. ... we are absolutely planning to move forward. We defend our portfolio in other areas.
Answered
Medium priority
Update on generics business and double-digit growth aspiration
Asked by Shyam Srinivasan, Goldman Sachs
Management acknowledged the shortfall and provided a clear timeline for recovery.
Read the exchange
Question
If we could get an update on I think we had earlier aspirations to grow double-digit, but we seem to be struggling. So it's just an update on the generics, please.
Siddharth Mittal, CEO and Managing Director, Biocon Limited
We are looking at double-digit growth. Unfortunately, in FY 2024, that looks unlikely. ... we should be able to get back to the mid-teens kind of growth level in the next fiscal.
Partial answer
High priority
Deleveraging plan and cash flow concerns
Asked by Shyam Srinivasan, Goldman Sachs
Management did not directly answer whether cash flows are slower but reiterated focus on debt reduction.
did not confirm or deny slower cash flowsvague on divestment necessity
Read the exchange
Question
Just trying to understand the acknowledgment that when we reduce the $200 million net debt number, is it an acknowledgment that our current cash flows are slower than anticipated, which is why we have to do these divestments?
Peter Bains, Group CEO, Biocon
Clearly looking at the balance sheet is a focus ... we've reduced acquisition-related debt in BBL by $200 million. We want to reduce it further, and we will be looking at a range of options. Clearly, cash flow will be one from the operations.
Partial answer
High priority
Growth outlook for biosimilars over next 12-15 months
Asked by Tushar Manudhane, Motilal Oswal
Management discussed growth strategies but did not provide any quantitative growth expectations or targets.
no quantitative growth guidancequalitative only
Read the exchange
Question
Given these circumstances, how to think about growth, particularly for biosimilars business over the next 12-15 months?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics
We see opportunity in the existing products growing through market share. ... we would look to see a twofold strategy there. One is to penetrate the couple of countries that we are present in with more products. And second is to see if we can widen our reach.